Dagmar Busse

1.3k total citations
22 papers, 1.0k citations indexed

About

Dagmar Busse is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Dagmar Busse has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Dagmar Busse's work include Pharmacogenetics and Drug Metabolism (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Dagmar Busse is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Dagmar Busse collaborates with scholars based in Germany, United States and Ireland. Dagmar Busse's co-authors include Michel Eichelbaum, H. Kroemer, Martin F. Fromm, Carlos L. Arteaga, W. Michael Flanagan, Frank Bohnenstengel, F. Michael Yakes, Anne E.G. Lenferink, Laura K. Shawver and James O. Price and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Dagmar Busse

22 papers receiving 1.0k citations

Peers

Countries citing papers authored by Dagmar Busse

Since Specialization

Citations

This map shows the geographic impact of Dagmar Busse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dagmar Busse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dagmar Busse more than expected).

Fields of papers citing papers by Dagmar Busse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dagmar Busse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dagmar Busse. The network helps show where Dagmar Busse may publish in the future.

Co-authorship network of co-authors of Dagmar Busse

This figure shows the co-authorship network connecting the top 25 collaborators of Dagmar Busse. A scholar is included among the top collaborators of Dagmar Busse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dagmar Busse. Dagmar Busse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI – Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results 2021 ·Oncology ·Axel Wein, Robert Stoehr, Stephan Kersting, Jürgen Siebler, Susanne Merkel, Dagmar Busse, Kerstin Wolff, (unknown), Clemens Neufert, Francesco Vitali, Markus Eckstein, (unknown), (unknown), W Schreiner, Michael Uder, Arndt Hartmann, Markus F. Neurath, Robert Grützmann	1
2	Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC) 2017 ·Anticancer Research ·Axel Wein, Juergen Siebler, Kerstin Wolff, (unknown), Dagmar Busse, Alexander Hagel, Franz Koch, Kirsten Merx, Markus F. Neurath, Ralf‐Dieter Hofheinz	3
3	Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option 2016 ·Case Reports in Oncology ·Axel Wein, Jürgen Siebler, Ruediger S. Goertz, Kerstin Wolff, (unknown), Dagmar Busse, Andreas E. Kremer, Franz Koch, Alexander Hagel, Michael Farnbacher, (unknown), Markus F. Neurath, (unknown)	1
4	Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing 2011 ·Medical Science Monitor ·(unknown), Axel Wein, Peter C. Konturek, Heinz Albrecht, Udo Reulbach, (unknown), Kerstin Wolff, (unknown), Dagmar Busse, Henriette Golcher, Claus Schildberg, Rolf Janka, Werner Hohenberger, Eckhart G. Hahn, Jürgen Siebler, Markus F. Neurath, Frank Boxberger	7
5	Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin???s Lymphoma and its Effect on Myelotoxicity 2007 ·Clinical Pharmacokinetics ·(unknown), Alexander Jetter, Stephan Rietbrock, Dirk Kasel, Andreas Engert, Andreas Josting, Beate Klimm, Georg Hempel, Stefanie Reif, Ulrich Jaehde, (unknown), Dagmar Busse, Matthias Schwab, Volker Diehl, Uwe Fuhr	16
6	Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study 2006 ·European Journal of Clinical Pharmacology ·Dagmar Busse, (unknown), Gerd Mikus, Matthias Schwab, Ute Hofmann, Michel Eichelbaum, Kari T. Kivistö	19
7	Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency 2002 ·Kidney International ·Marion Haubitz, Frank Bohnenstengel, R. Brunkhorst, Matthias Schwab, Ute Hofmann, Dagmar Busse	106
8	Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration 2002 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Dagmar Busse, Gudrun Würthwein, (unknown), Georg Hempel, Martin F. Fromm, Michel Eichelbaum, Heyo K. Kroemer, (unknown)	7
9	Population pharmacokinetics of cyclo- phosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy 2002 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Alexander Jetter, (unknown), Stephan Rietbrock, (unknown), M. Sieber, Hans Tesch, G. Hempel, Dagmar Busse, Matthias Schwab, Stefanie Reif, Ulrich Jaehde, Volker Diehl, Uwe Fuhr	7
10	ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. 2001 ·PubMed ·Anne E.G. Lenferink, Dagmar Busse, W. Michael Flanagan, F. Michael Yakes, Carlos L. Arteaga	156
11	Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance 2001 ·Seminars in Oncology ·Dagmar Busse	27
12	Disposition and pharmacologic effects of R/S‐verapamil in patients with chronic atrial fibrillation: An investigation comparing single and multiple dosing 2001 ·Clinical Pharmacology & Therapeutics ·Dagmar Busse, Martin F. Fromm, Klaus Mörike, Siegfried Drescher, Volker Kühlkamp, Michel Eichelbaum	11
13	Reversible G1 Arrest Induced by Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Requires Up-regulation of p27KIP1 Independent of MAPK Activity 2000 ·Journal of Biological Chemistry ·Dagmar Busse, (unknown), (unknown), William E. Russell, James O. Price, W. Michael Flanagan, Laura K. Shawver, Carlos L. Arteaga	178
14	HER-2/neu (erbB-2) and the cell cycle. 2000 ·PubMed ·Dagmar Busse, (unknown), Carlos L. Arteaga	23
15	Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism 1999 ·Cancer Chemotherapy and Pharmacology ·Dagmar Busse, (unknown), (unknown), Frank Bohnenstengel, Michel Eichelbaum, Peter Fischer, Kurt R. Schumacher, Walter E. Aulitzky, Heyo K. Kroemer	33
16	Gut wall metabolism of verapamil in older people: effects of rifampicin‐mediated enzyme induction 1998 ·British Journal of Clinical Pharmacology ·Martin F. Fromm, Karin Dilger, Dagmar Busse, Heyo K. Kroemer, Michel Eichelbaum, Ulrich Klotz	39
17	Fortschritte in der Therapie von Tumorerkrankungen mit Zytostatika: Untersuchungen zur Hochdosistherapie mit Cyclophosphamid und zum Drug Targeting von Doxorubicin 1998 ·Pharmazie in unserer Zeit ·Dagmar Busse, H K Kroemer, Bernhard Sperker, Thomas E. Mürdter	1
18	Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. 1997 ·Journal of Clinical Oncology ·Dagmar Busse, F.W. Busch, Frank Bohnenstengel, Michel Eichelbaum, Peter Fischer, Joanna Opalinska, Kurt R. Schumacher, (unknown), H K Kroemer	91
19	Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin 1996 ·Hepatology ·Martin F. Fromm, Dagmar Busse, H. Kroemer, Michel Eichelbaum	214
20	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans 1995 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Dagmar Busse, José Cosme, Philippe Beaune, H. Kroemer, Michel Eichelbaum, (unknown)	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact